# Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia

## TL;DR

This review explores how corticosteroids can help treat severe pediatric pneumonia caused by Mycoplasma, but more research is needed to determine the best use.

## Contribution

The paper provides a narrative review of corticosteroid efficacy in pediatric Mycoplasma pneumonia, highlighting timing, dosage, and clinical outcomes.

## Key findings

- Early corticosteroid administration improves fever resolution and radiological recovery in pediatric Mycoplasma pneumonia.
- High-dose corticosteroids are effective in severe or refractory cases, while inhaled forms benefit milder cases.

## Abstract

What are the main findings?
This narrative review summarizes evidence on corticosteroid use in pediatric Mycoplasma pneumoniae pneumonia, including dosage, timing, and clinical outcomes.Despite heterogeneous data, corticosteroids—especially in moderate-to-severe or refractory cases—may improve fever resolution, radiological recovery, and inflammatory markers.

This narrative review summarizes evidence on corticosteroid use in pediatric Mycoplasma pneumoniae pneumonia, including dosage, timing, and clinical outcomes.

Despite heterogeneous data, corticosteroids—especially in moderate-to-severe or refractory cases—may improve fever resolution, radiological recovery, and inflammatory markers.

What are the implications of the main findings?
A standardized approach to corticosteroid use in Mycoplasma pneumoniae pneumonia is lacking; this review highlights the need for well-designed randomized controlled trials.Clinicians should balance potential benefits and risks, particularly in young children or when using high-dose or systemic corticosteroids.

A standardized approach to corticosteroid use in Mycoplasma pneumoniae pneumonia is lacking; this review highlights the need for well-designed randomized controlled trials.

Clinicians should balance potential benefits and risks, particularly in young children or when using high-dose or systemic corticosteroids.

Background/Objectives: To summarize the available evidence on the use of corticosteroids in the treatment of pediatric Mycoplasma pneumoniae pneumonia, including severe and refractory forms. Methods: We conducted a narrative literature review of studies published between 2000 and 2024 that investigated corticosteroid therapy in children with Mycoplasma pneumoniae pneumonia, including various clinical presentations such as severe Mycoplasma pneumoniae pneumonia and refractory Mycoplasma pneumoniae pneumonia. Both randomized controlled trials and observational studies were included. Results: Early administration of corticosteroids, particularly within 24–36 h of hospital admission, was associated with improved clinical outcomes, including faster fever resolution, shorter hospital stay, and enhanced radiological recovery. High-dose regimens (≥5 mg/kg/day) or pulse therapy appeared effective in severe or refractory cases, while inhaled corticosteroids showed benefit in milder forms. Predictive factors for corticosteroid response included elevated C-reactive protein, lactate dehydrogenase, and ferritin levels. The overall safety profile was acceptable, with minimal adverse effects reported in most studies. Conclusions: Corticosteroids may play a beneficial role as adjunctive therapy in pediatric Mycoplasma pneumoniae pneumonia, especially in selected cases. However, further high-quality studies are required to define optimal timing, dosage, and patient selection.